newsfilter
← Latest News
GlobeNewswire·

Immunocore reports third quarter financial results and provides a business update

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous